IQV
Bearish signalScored 2026-10-04 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
IQVIA Holdings Inc.
- Nom
- IQVIA Holdings Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Diagnostics & Research
- Bourse
- NYSE
- Capitalisation
- $45.7B
- Employés
- 94,000
- PDG
- Ari Bousbib
- Site web
- https://www.iqvia.com
- Marché
- ALBBYCERTCRLFTREHCATICLR
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 106 279 titres (~26 261 540,90 $ US)
- Insiders
- BOUSBIB ARI
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$16,816,114
Avg sell (VWAP, 90d window) $244.52 vs last close $266.09 (+8.8%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-07-29
- Liquidity
- Liquid $435,160,220/day · 20d vol
- Last synced
-
2026-10-19 22:07:50
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-02 | Berkshire James G. | Sell · S | 2,668 | $261.33 | $697,228 | Form 4 |
| 2026-08-03 | STAUB W RICHARD | Sell · S | 5,500 | $232.68 | $1,279,740 | Form 4 |
| 2026-07-31 | Patel Bhavik | Sell · S | 1,855 | $235.27 | $436,426 | Form 4 |
| 2026-07-29 | BOUSBIB ARI | Sell · S | 53,191 | $244.78 | $13,020,093 | Form 4 |
| 2026-07-29 | Cherofsky Keriann | Sell · S | 558 | $245.21 | $136,827 | Form 4 |
| 2026-07-29 | Sherbet Eric | Sell · S | 5,000 | $249.16 | $1,245,800 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-09-14 | Kevin Hern | Sale (Full) | $15,001 - $50,000 |
| 2026-09-08 | Kevin Hern | Sale (Full) | $1,001 - $15,000 |
| 2026-09-03 | Kevin Hern | Sale (Full) | $1,001 - $15,000 |
| 2026-03-16 | Kevin Hern | Sale (Full) | $50,001 - $100,000 |
| 2026-01-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-05-15 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-04-08 | Robert P. Bresnahan | Purchase | $15,001 - $50,000 |
| 2025-02-25 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-31 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-19 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-09 | Susie Lee | Sale (Full) | $1,001 - $15,000 |
| 2023-04-20 | Susie Lee | Sale (Partial) | $1,001 - $15,000 |
| 2023-04-10 | Daniel Goldman | Sale | $15,001 - $50,000 |
| 2023-03-14 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-01-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-07-20 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-07-14 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-07-14 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-07-12 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-07-12 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-07-12 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-07-06 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-07-06 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-07-06 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-05-23 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-05 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-04-22 | Kevin Hern | Sale (Full) | $1,001 - $15,000 |
| 2022-04-13 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-02-28 | Kurt Schrader | Sale (Full) | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-02-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-21 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-01-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2021-08-11 | Kurt Schrader | Sale (Full) | $1,001 - $15,000 |
| 2021-05-20 | Kevin Hern | Purchase | $1,001 - $15,000 |
| 2021-05-18 | Kevin Hern | Purchase | $100,001 - $250,000 |
| 2021-04-23 | Kurt Schrader | Sale (Full) | $1,001 - $15,000 |
| 2020-12-16 | Susie Lee | Purchase | $1,001 - $15,000 |
| 2020-11-04 | Gilbert Cisneros | Sale (Full) | $1,001 - $15,000 |
| 2020-11-03 | Gilbert Cisneros | Sale (Partial) | $15,001 - $50,000 |
| 2020-09-24 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2020-09-23 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2020-06-04 | Susie Lee | Sale (Partial) | $1,001 - $15,000 |
| 2020-05-19 | Susie Lee | Sale (Partial) | $1,001 - $15,000 |
| 2019-12-18 | John B. Larson | Sale (Full) | $1,001 - $15,000 |
| 2019-04-25 | Susie Lee | Purchase | $1,001 - $15,000 |
| 2019-02-27 | Susie Lee | Purchase | $1,001 - $15,000 |
| 2019-02-05 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2019-01-29 | Susie Lee | Sale (Full) | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-10-04 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
IQV presents a near-zero financial health profile with no usable liquidity or fundamental trend data, making any constructive investment thesis impossible to substantiate.
The first sentence of the analysis written for IQV on 2026-10-04 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 0.75 · operating margin 13% — readings disagree
Suggested stop 237.34, nearest stored support minus 0.5 ATR(10.8% under the last close). Reward/risk to the next stored resistance is 0.20. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 33.3% | 34.9% | 35.0% | 34.9% | 33.5% | |
| Ebit Margin | 14.1% | 15.2% | 14.2% | 12.3% | 10.8% | |
| Ebitda Margin | 18.0% | 22.4% | 21.7% | 20.2% | 19.9% | |
| Operating Profit Margin | 13.4% | 14.3% | 13.2% | 12.5% | 10.0% | |
| Pretax Profit Margin | 9.9% | 10.8% | 9.7% | 9.4% | 8.2% | |
| Continuous Operations Profit Margin | 8.3% | 8.9% | 9.1% | 7.6% | 7.0% | |
| Net Profit Margin | 8.3% | 8.9% | 9.1% | 7.6% | 7.0% | |
| Bottom Line Profit Margin | 8.3% | 8.9% | 9.1% | 7.6% | 7.0% | |
| Current Ratio | 0.749 | 0.838 | 0.862 | 0.893 | 0.909 | |
| Quick Ratio | 0.749 | 0.838 | 0.862 | 0.893 | 0.909 | |
| Solvency Ratio | 0.086 | 0.119 | 0.121 | 0.113 | 0.120 | |
| Cash Ratio | 0.237 | 0.245 | 0.212 | 0.218 | 0.261 | |
| Price To Earnings Ratio | 28.497 | 25.959 | 31.310 | 35.204 | 55.869 | |
| Price To Earnings Growth Ratio | 6.345 | 10.658 | 1.161 | 2.309 | 0.227 | |
| Forward Price To Earnings Growth Ratio | 6.345 | 10.658 | 1.161 | 2.309 | 0.227 | |
| Price To Earnings Diluted Ratio | 28.751 | 26.236 | 31.739 | 35.820 | 56.998 | |
| Price To Earnings Diluted Growth Ratio | 6.153 | 9.563 | 1.156 | 2.303 | 0.232 | |
| Price To Book Ratio | 5.958 | 5.872 | 6.958 | 6.667 | 8.938 | |
| Price To Sales Ratio | 2.376 | 2.313 | 2.838 | 2.667 | 3.892 | |
| Price To Free Cash Flow Ratio | 18.892 | 16.853 | 28.352 | 24.235 | 23.459 | |
| Price To Operating Cash Flow Ratio | 14.600 | 13.118 | 19.790 | 17.008 | 18.355 | |
| Debt To Assets Ratio | 0.540 | 0.526 | 0.521 | 0.514 | 0.504 | |
| Debt To Equity Ratio | 2.487 | 2.333 | 2.274 | 2.257 | 2.059 | |
| Debt To Capital Ratio | 0.713 | 0.700 | 0.695 | 0.693 | 0.673 | |
| Long Term Debt To Capital Ratio | 0.685 | 0.679 | 0.679 | 0.686 | 0.666 | |
| Financial Leverage Ratio | 4.605 | 4.434 | 4.365 | 4.395 | 4.086 | |
| Working Capital Turnover Ratio | -10.140 | -15.230 | -20.086 | -26.809 | 513.852 | |
| Operating Cash Flow Ratio | 0.318 | 0.390 | 0.331 | 0.405 | 0.561 | |
| Operating Cash Flow Sales Ratio | 0.163 | 0.176 | 0.143 | 0.157 | 0.212 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.773 | 0.778 | 0.698 | 0.702 | 0.782 | |
| Debt Service Coverage Ratio | 1.046 | 1.739 | 2.270 | 4.664 | 5.588 | |
| Interest Coverage Ratio | 2.993 | 3.287 | 2.942 | 4.325 | 3.715 | |
| Short Term Operating Cash Flow Coverage Ratio | 1.442 | 2.372 | 2.993 | 14.868 | 32.330 | |
| Operating Cash Flow Coverage Ratio | 0.164 | 0.192 | 0.155 | 0.174 | 0.237 | |
| Capital Expenditure Coverage Ratio | 4.401 | 4.512 | 3.311 | 3.353 | 4.597 | |
| Dividend Paid And Capex Coverage Ratio | 4.401 | 4.512 | 3.311 | 3.353 | 4.597 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 18.020 | 13.924 | 16.907 | 17.268 | 23.518 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 33.3% | ▼-1.6% | ▼-1.0% |
| Ebit Margin | 14.1% | ▼-1.1% | ▲0.8% |
| Ebitda Margin | 18.0% | ▼-4.4% | ▼-2.4% |
| Operating Profit Margin | 13.4% | ▼-0.9% | ▲0.7% |
| Pretax Profit Margin | 9.9% | ▼-0.9% | ▲0.3% |
| Continuous Operations Profit Margin | 8.3% | ▼-0.6% | ▲0.2% |
| Net Profit Margin | 8.3% | ▼-0.6% | ▲0.2% |
| Bottom Line Profit Margin | 8.3% | ▼-0.6% | ▲0.2% |
| Current Ratio | 0.750 | ▼-0.088 | ▼-0.101 |
| Quick Ratio | 0.750 | ▼-0.088 | ▼-0.101 |
| Solvency Ratio | 0.086 | ▼-0.034 | ▼-0.026 |
| Cash Ratio | 0.237 | ▼-0.007 | ▲0.003 |
| Price To Earnings Ratio | 28.497 | ▲2.538 | ▼-6.871 |
| Price To Earnings Growth Ratio | 6.345 | ▼-4.313 | ▲2.205 |
| Forward Price To Earnings Growth Ratio | 6.345 | ▼-4.313 | ▲2.205 |
| Price To Earnings Diluted Ratio | 28.751 | ▲2.515 | ▼-7.158 |
| Price To Earnings Diluted Growth Ratio | 6.153 | ▼-3.410 | ▲2.272 |
| Price To Book Ratio | 5.958 | ▲0.086 | ▼-0.920 |
| Price To Sales Ratio | 2.376 | ▲0.063 | ▼-0.442 |
| Price To Free Cash Flow Ratio | 18.892 | ▲2.039 | ▼-3.466 |
| Price To Operating Cash Flow Ratio | 14.600 | ▲1.482 | ▼-1.974 |
| Debt To Assets Ratio | 0.540 | ▲0.014 | ▲0.019 |
| Debt To Equity Ratio | 2.487 | ▲0.154 | ▲0.205 |
| Debt To Capital Ratio | 0.713 | ▲0.013 | ▲0.018 |
| Long Term Debt To Capital Ratio | 0.684 | ▲0.005 | ▲0.005 |
| Financial Leverage Ratio | 4.605 | ▲0.171 | ▲0.228 |
| Working Capital Turnover Ratio | -10.140 | ▲5.090 | ▼-98.457 |
| Operating Cash Flow Ratio | 0.318 | ▼-0.072 | ▼-0.083 |
| Operating Cash Flow Sales Ratio | 0.163 | ▼-0.014 | ▼-0.007 |
| Free Cash Flow Operating Cash Flow Ratio | 0.773 | ▼-0.006 | ▲0.026 |
| Debt Service Coverage Ratio | 1.046 | ▼-0.694 | ▼-2.016 |
| Interest Coverage Ratio | 2.993 | ▼-0.293 | ▼-0.459 |
| Short Term Operating Cash Flow Coverage Ratio | 1.442 | ▼-0.930 | ▼-9.359 |
| Operating Cash Flow Coverage Ratio | 0.164 | ▼-0.028 | ▼-0.020 |
| Capital Expenditure Coverage Ratio | 4.401 | ▼-0.110 | ▲0.366 |
| Dividend Paid And Capex Coverage Ratio | 4.401 | ▼-0.110 | ▲0.366 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 18.020 | ▲4.095 | ▲0.092 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $38.75B | $35.63B | $42.53B | $38.44B | $54.00B | |
| Enterprise value | $52.94B | $48.08B | $55.05B | $50.23B | $65.07B | |
| EV / Sales | 3.25x | 3.12x | 3.67x | 3.49x | 4.69x | |
| EV / Op. cash flow | 19.95x | 17.70x | 25.61x | 22.23x | 22.12x | |
| EV / Free cash flow | 25.81x | 22.74x | 36.70x | 31.67x | 28.27x | |
| EV / EBITDA | 18.02x | 13.92x | 16.91x | 17.27x | 23.52x | |
| Net debt / EBITDA | 4.83x | 3.61x | 3.85x | 4.05x | 4.00x | |
| Current ratio | 0.75x | 0.84x | 0.86x | 0.89x | 0.91x | |
| Income quality | 1.95x | 1.98x | 1.58x | 2.07x | 3.05x | |
| Graham number | $82 | $76 | $74 | $63 | $60 | |
| Graham net-net | -$108 | -$91 | -$90 | -$86 | -$79 | |
| Tax burden | 84.3% | 82.3% | 93.1% | 80.8% | 85.2% | |
| Interest burden | 70.2% | 71.4% | 68.5% | 75.9% | 75.4% | |
| Working capital | -$2.09B | -$1.13B | -$895.0M | -$597.0M | -$478.0M | |
| Invested capital | $20.31B | $18.85B | $19.33B | $19.01B | $18.67B | |
| Return on assets | 4.5% | 5.1% | 5.1% | 4.3% | 3.9% | |
| Operating ROA | 7.7% | 8.2% | 7.6% | 7.2% | 5.7% | |
| Return on tangible assets | 16.3% | 17.9% | 18.7% | 16.5% | 15.0% | |
| Return on equity | 20.9% | 22.6% | 22.2% | 18.9% | 16.0% | |
| Return on invested capital | 7.9% | 8.6% | 8.8% | 7.3% | 6.1% | |
| Return on capital employed | 10.1% | 11.0% | 9.8% | 9.1% | 7.2% | |
| Earnings yield | 3.5% | 3.9% | 3.2% | 2.8% | 1.8% | |
| Free cash flow yield | 5.3% | 5.9% | 3.5% | 4.1% | 4.3% | |
| Capex / Op. cash flow | 22.7% | 22.2% | 30.2% | 29.8% | 21.8% | |
| Capex / Depreciation | 52.7% | 54.0% | 57.7% | 59.6% | 50.6% | |
| Capex / Sales | 3.7% | 3.9% | 4.3% | 4.7% | 4.6% | |
| SG&A / Sales | 12.2% | 12.9% | 13.7% | 14.4% | 14.2% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 1.5% | 1.3% | 1.4% | 1.3% | 1.2% | |
| Intangibles / Total assets | 72.1% | 71.4% | 72.7% | 74.0% | 73.9% | |
| Days sales outstanding | 77d | 77d | 83d | 75d | 69d | |
| Days payables outstanding | 126d | 27d | 27d | 25d | 25d | |
| Operating cycle | 77d | 77d | 83d | 75d | 69d | |
| Cash conversion cycle | -49d | 50d | 57d | 50d | 44d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-16 First Citizens Bank & Trust Co. Makes New $1.39 Million Investment in IQVIA Holdings Inc. $IQV First Citizens Bank and Trust Co. acquired a new position in shares of IQVIA Holdings Inc. (NYSE: IQV) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 5,160 shares of the medical research company''s stock, valued at approximately $1,387,000. Several other institutional investors
- 2026-10-13 IQVIA Selects Veeva Clinical Operations Applications RESEARCH TRIANGLE PARK, N.C. and PLEASANTON, Calif.
- 2026-10-13 IQVIA Selects Veeva Clinical Operations Applications RESEARCH TRIANGLE PARK, N.C. & PLEASANTON, Calif.--(BUSINESS WIRE)--IQVIA (NYSE:IQV) and Veeva Systems (NYSE: VEEV) today announced an expansion of their partnership with the selection of Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications that will be used across IQVIA clinical development studies. This extends the previously announced EDC partnership. Together, IQVIA and Veeva bring best-in-class capabilities to clinical research to help customers increase tr.
- 2026-10-08 Here''s Why IQVIA Holdings (IQV) is a Strong Momentum Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 2026-10-07 IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today at TechIQ 2026 introduced IQVIA Life Science ModelsTM to help predict clinical trial outcomes. IQVIA Life Science Models are a suite of purpose-built models for life sciences, combining IQVIA''s proprietary expert content, deep domain knowledge and established regulatory, com.
- 2026-10-07 IQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today at TechIQ 2026 introduced IQVIA Explorer™ to help customers make better-informed commercial decisions. IQVIA Explorer turns complex, one-time analytics projects into an always-on commercial intelligence capability. Users can apply external indicators and ask business questio.
- 2026-10-02 Extensive Database & Solid Bookings Benefit IQVIA Amid Low Liquidity IQV''s vast healthcare database, AI-enabled capabilities and strong R&DS bookings support growth, while low liquidity and $14.1B net debt remain in focus.
- 2026-09-29 Rep. Kevin Hern Unloads Shares of Honeywell International Inc. (NASDAQ:HON) Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Honeywell International Inc. (NASDAQ: HON). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $15,001 and $50,000 in Honeywell International stock on August 31st. The trade occurred in the Representative''s "HERN FAMILY FOUNDATION" account. Representative Kevin Hern also recently made the following
- 2026-09-29 Crane (NYSE:CR) Stock Sold Off by Rep. Kevin Hern Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Crane (NYSE: CR). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $50,001 and $100,000 in Crane stock on August 31st. The trade occurred in the Representative''s "HERN FAMILY FOUNDATION" account. Representative Kevin Hern also recently made the following trade(s): Sold $15,001
- 2026-09-29 Colgate-Palmolive (NYSE:CL) Stock Sale Revealed by Rep. Kevin Hern Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Colgate-Palmolive Company (NYSE: CL). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $1,001 and $15,000 in Colgate-Palmolive stock on August 27th. The trade occurred in the Representative''s "KEVIN HERN TRADITIONAL IRA" account. Representative Kevin Hern also recently made the following trade(s):